"North America Topical Drug Delivery Market" – Trends and Forecast to 2024

SUBSCRIBE FOR UPDATED REPORTS

Get great contents delivered straight to your inbox everyday, just a click away, Sign Up Now.
Name
Email
US : +1-888-387-2818
UK : +44-161-394-0625
Want create site? Find Free WordPress Themes and plugins.

North America Topical Drug Delivery Market – Trends and Forecast to 2024

North America
Upcoming Reports
North America Topical drug delivery market
  • No of pages :
    175
  • No of Figures:
    30
  • No of Tables:
    125
  • Report Type:
    Upcoming
  • Category:

North America Topical Drug Delivery Market, By Product Type {Topical Drug Delivery Formulations (Solid, Liquid, Semi-Solid), Transdermal Drug Delivery Devices (Patches, Gels)}, End-User (Hospitals, Clinics, Home Healthcare, Diagnostic Centers, Others), Distribution Channel (Direct Tenders, Retail), Country (U.S, Canada, Mexico) – Trends and Forecast to 2024

Want create site? Find Free WordPress Themes and plugins.

North America Topical Drug Delivery Market is expected to reach USD 89.3 billion by 2024 from USD 48.0 billion in 2016, growing at a CAGR of 8.0% in the forecast period 2017 to 2024. The new market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

The North America Topical Drug Delivery Market is segmented on the basis of product type, distribution channel, end user, and geography.

On the basis of product typethe market is segmented into transdermal drug delivery devices and topical drug  delivery formulations. Topical drug delivery formulations are further segmented based on form into solid, semi-solid, and liquid. The semi solid segment is further classified into ointments, creams, lotions, gels, and pastes. The solid drugs segment is further segmented into powders and suppositors. The liquid drugs segment is further classified into solutions and suspensions.

The transdermal drug delivery devices market segment is further segmented into patches and gels. In 2016, on the basis of product type topical drug delivery formulations segment dominated the market by 72.6% share, however transdermal drug delivery devices market is expected to grow at the highest CAGR of 14.1% in the forecast period 2017 to 2024.

On the basis of end users, the market is segmented into hospitals, home healthcare, clinics, diagnostic centers, and others.

Based on country, the market is segmented into U.S, Canada, and  Mexico.

The North America topical drug delivery market is highly fragmented with various companies operating in local regions. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.

Some of the major players operating in this market are MedPharm, Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services Inc A J&J Company), Crescita Therapeutics, Galderma S.A., Biofarmitalia s.r.l, Pharmatek Laboratories, Inc., Stiefel Laboratories, Inc., Tapemark, Acrux Limited, Nitto Denko Corporation, Valeant Pharmaceuticals International, Inc., Skinvisible Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co., Inc., Pocono Coated Products LLC, TheraSolve NV., Samyang Biopharmaceuticals Corporation, Lohmann Therapie-Systeme AG, Prosollus Pharmaceuticals, Easton Pharmaceuticals Inc., Novosis AG, Antares Pharma, Inc., Endo Pharmaceuticals Inc., Transdermal Technologies, Inc., Sheffield Pharmaceuticals, Inc., Solvay, and 3M Drug Delivery Systems.

Did you find apk for android? You can find new Free Android Games and apps.
Choose Licence Type

Enterprise, Single User

Reviews

There are no reviews yet.

Be the first to review “North America Topical Drug Delivery Market – Trends and Forecast to 2024”

Want create site? Find Free WordPress Themes and plugins.

1. INTRODUCTION

      1.1. OVERVIEW OF THE NORTHA AMERICA TOPICAL DRUG DELIVERY MARKET
      1.2. MARKET SEGMENTATION & COVERAGE
               1.2.1. CURRENCY AND PRICING
               1.2.2. LIMITATION
               1.2.3. STAKEHOLDERS

2. RESEARCH METHODOLOGY

      2.1. KEY TAKEAWAYS
     2.2. ARRIVING AT THE NORTH AMERICA TOPICAL DRUG DELIVERY MARKET SIZE
              2.2.1. MARKET CRACKDOWN APPROACH
              2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
              2.2.3. DATA TRIANGULATION
              2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
              2.2.5. PRODUCT PIPELINE ANALYSIS
              2.2.6. PORTER’S FIVE FORCES MATRIX
     2.4. NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
     2.5. ASSUMPTIONS

3. MARKET LANDSCAPE SUMMARY

4. PREMIUM INSIGHTS

       4.1. OVERVIEW
       4.2. NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
       4.3. MARKET OVERVIEW
                4.3.1. DRIVERS
                           4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASE SUCH AS DIABETES
                           4.3.1.2. GROWTH IN TRANSDERMAL TECHNOLOGY
                           4.3.1.3. INNOVATION AND DEVELOPMENT OF NEW DRUG TYPES
                           4.3.1.4. BETTER HEALTHCARE SPENDING IN SOUTH ASIA AND AFRICA
                 4.3.2. RESTRAINTS
                 4.3.3. OPPURTUNITIES
                 4.3.4. THREATS
       4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES

5. EXECUTIVE SUMMARY

6. TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE

        6.1. OVERVIEW
        6.2. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
                 6.2.1. TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE
                            6.2.1.1. TRANSDERMAL PATCHES
                            6.2.1.2. TRANSDERMAL GELS
                           6.2.2. TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM
                           6.2.2.1. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
                           6.2.2.1.1. SOLUTIONS
                           6.2.2.1.2.  SUSPENSIONS
                           6.2.2.2.  SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
                           6.2.2.2.1.  GELS
                           6.2.2.2.2.  CREAMS
                           6.2.2.2.3.  OINTMENTS
                           6.2.2.2.4.  PASTES
                           6.2.2.2.5.  LOTIONS
                           6.2.2.3.  SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
                           6.2.2.3.1.  SUPPOSITORIES
                           6.2.2.3.2.  POWDERS

7. TOPICAL DRUG DELIVERY MARKET, BY END-USER

        7.1. OVERVIEW
        7.2. HOSPITALS
        7.3. HOME HEALTHCARE
        7.4. CLINICS
        7.5. DIAGNOSTIC CENTERS
        7.6. OTHERS

8. TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

        8.1. OVERVIEW
       8.2. HOSPITAL PHARMACIES
       8.3. PHARMACY STORES
       8.4. DIRECT TENDERS
       8.5. ONLINE PHARMACY

9. TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY

      9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
              9.1.1. NORTH AMERICA
                         9.1.1.1. U.S.
                         9.1.1.2. CANADA
                         9.1.1.3. MEXICO

9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

10. TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE

            10.1. NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.2. U.S. TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.3. EUROPE TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.4. APAC TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.5. SOUTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.6. MIDDLE EAST AND AFRICA  TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
            10.7. MERGERS & ACQUISITIONS
            10.8. NEW PRODUCT DEVELOPMENT & APPROVALS
            10.10. EXPANSIONS
            10.10. REGULATORY CHANGES
            10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

11. TOPICAL DRUG DELIVERY MARKET, COMPANY PROFILES

          11.1. JANSSEN PHARMACEUTICALS, INC. (A J&J COMPANY)
                     11.1.1. COMPANY OVERVIEW
                     11.1.2. SWOT ANALYSIS
                     11.1.3. REVENUE ANALYSIS
                     11.1.4. PRODUCT PORTFOLIO
                     11.1.5. RECENT DEVELOPEMENTS
                     11.1.5. DATA BRIDGE ANALYSIS
         11.2. CRESCITA THERAPEUTICS
                    11.2.1. COMPANY OVERVIEW
                    11.2.2. SWOT ANALYSIS
                    11.2.3. REVENUE ANALYSIS
                    11.2.4. PRODUCT PORTFOLIO
                    11.2.5. RECENT DEVELOPEMENTS
                    11.2.5. DATA BRIDGE ANALYSIS
         11.3. GALDERMA S.A.
                    11.3.1. COMPANY OVERVIEW
                    11.3.2. SWOT ANALYSIS
                    11.3.3. REVENUE ANALYSIS
                    11.3.4. PRODUCT PORTFOLIO
                    11.3.5. RECENT DEVELOPEMENTS
                    11.3.6. DATA BRIDGE ANALYSIS
         11.4. BIOFARMITALIA S.R.L
                    11.4.1. COMPANY OVERVIEW
                    11.4.2. SWOT ANALYSIS
                    11.4.3. REVENUE ANALYSIS
                    11.4.4. PRODUCT PORTFOLIO
                    11.4.5. RECENT DEVELOPEMENTS
                    11.4.5. DATA BRIDGE ANALYSIS
         11.5. PHARMATEK LABORATORIES, INC.
                    11.5.1. COMPANY OVERVIEW
                    11.5.2. SWOT ANALYSIS
                    11.5.3. REVENUE ANALYSIS
                    11.5.4. PRODUCT PORTFOLIO
                    11.5.5. RECENT DEVELOPEMENTS
                    11.5.5. DATA BRIDGE ANALYSIS
         11.6. STIEFEL LABORATORIES, INC.
                    11.6.1. COMPANY OVERVIEW
                    11.6.2. SWOT ANALYSIS
                    11.6.3. REVENUE ANALYSIS
                    11.6.4. PRODUCT PORTFOLIO
                    11.6.5. RECENT DEVELOPEMENTS
                    11.6.5. DATA BRIDGE ANALYSIS
         11.7. TAPEMARK
                    11.7.1. COMPANY OVERVIEW
                    11.7.2. SWOT ANALYSIS
                    11.7.3. REVENUE ANALYSIS
                    11.7.4. PRODUCT PORTFOLIO
                    11.7.5. RECENT DEVELOPEMENTS
                    11.7.6. DATA BRIDGE ANALYSIS
         11.8. NITTO DENKO CORPORATION
                    11.8.1. COMPANY OVERVIEW
                    11.8.2. SWOT ANALYSIS
                    11.8.3. REVENUE ANALYSIS
                    11.8.4. PRODUCT PORTFOLIO
                    11.8.5. RECENT DEVELOPEMENTS
                    11.8.6. DATA BRIDGE ANALYSIS
         11.9. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
                    11.9.1. COMPANY OVERVIEW
                    11.9.2. SWOT ANALYSIS
                    11.9.3. REVENUE ANALYSIS
                    11.9.4. PRODUCT PORTFOLIO
                    11.9.5. RECENT DEVELOPEMENTS
                    11.9.6. DATA BRIDGE ANALYSIS
         11.9. MYLAN PHARMACEUTICALS INC.
                    11.9.1. COMPANY OVERVIEW
                    11.9.2. SWOT ANALYSIS
                    11.9.3. REVENUE ANALYSIS
                    11.9.4. PRODUCT PORTFOLIO
                    11.9.5. RECENT DEVELOPEMENTS
                    11.9.6. DATA BRIDGE ANALYSIS
         11.9. HISAMITSU PHARMACEUTICAL CO., INC.
                     11.9.1. COMPANY OVERVIEW
                     11.9.2. SWOT ANALYSIS
                     11.9.3. REVENUE ANALYSIS
                     11.9.4. PRODUCT PORTFOLIO
                     11.9.5. RECENT DEVELOPEMENTS
                     11.9.5. DATA BRIDGE ANALYSIS
         11.10. THERASOLVE NV.
                       11.10.1. COMPANY OVERVIEW
                       11.10.2. SWOT ANALYSIS
                       11.10.3. REVENUE ANALYSIS
                       11.10.4. PRODUCT PORTFOLIO
                       11.10.5. RECENT DEVELOPEMENTS
                       11.10.6. DATA BRIDGE ANALYSIS
         11.11. SAMYANG BIOPHARMACEUTICALS CORPORATION
                       11.11.1. COMPANY OVERVIEW
                       11.11.2. SWOT ANALYSIS
                       11.11.3. REVENUE ANALYSIS
                       11.11.4. PRODUCT PORTFOLIO
                       11.11.5. RECENT DEVELOPEMENTS
                       11.11.6. DATA BRIDGE ANALYSIS
         11.12. LOHMANN THERAPIE-SYSTEME AG
                       11.12.1. COMPANY OVERVIEW
                       11.12.2. SWOT ANALYSIS
                       11.12.3. REVENUE ANALYSIS
                       11.12.4. PRODUCT PORTFOLIO
                       11.12.5. RECENT DEVELOPEMENTS
                       11.12.6. DATA BRIDGE ANALYSIS
         11.13. PROSOLLUS PHARMACEUTICALS
                       11.13.1. COMPANY OVERVIEW
                       11.13.2. SWOT ANALYSIS
                       11.13.3. REVENUE ANALYSIS
                       11.13.4. PRODUCT PORTFOLIO
                       11.13.5. RECENT DEVELOPEMENTS
                       11.13.6. DATA BRIDGE ANALYSIS
         11.14. EASTON PHARMACEUTICALS INC.
                       11.14.1. COMPANY OVERVIEW
                       11.14.2. SWOT ANALYSIS
                       11.14.3. REVENUE ANALYSIS
                       11.14.4. PRODUCT PORTFOLIO
                       11.14.5. RECENT DEVELOPEMENTS
                       11.14.6. DATA BRIDGE ANALYSIS
         11.15. ANTARES PHARMA, INC.
                       11.15.1. COMPANY OVERVIEW
                       11.15.2. SWOT ANALYSIS
                       11.15.3. REVENUE ANALYSIS
                       11.15.4. PRODUCT PORTFOLIO
                       11.15.5. RECENT DEVELOPEMENTS
                      11.15.6. DATA BRIDGE ANALYSIS
         11.16. ENDO PHARMACEUTICALS INC.
                       11.16.1. COMPANY OVERVIEW
                       11.16.2. SWOT ANALYSIS
                       11.16.3. REVENUE ANALYSIS
                       11.16.4. PRODUCT PORTFOLIO
                       11.16.5. RECENT DEVELOPEMENTS
                       11.16.6. DATA BRIDGE ANALYSIS
         11.17. TRANSDERMAL TECHNOLOGIES, INC.
                       11.17.1. COMPANY OVERVIEW
                       11.17.2. SWOT ANALYSIS
                       11.17.3. REVENUE ANALYSIS
                       11.17.4. PRODUCT PORTFOLIO
                       11.17.5. RECENT DEVELOPEMENTS
                       11.17.6. DATA BRIDGE ANALYSIS
         11.18. SHEFFIELD PHARMACEUTICALS, INC.
                       11.18.1. COMPANY OVERVIEW
                       11.18.2. SWOT ANALYSIS
                       11.18.3. REVENUE ANALYSIS
                       11.18.4. PRODUCT PORTFOLIO
                       11.18.5. RECENT DEVELOPEMENTS
                       11.18.6. DATA BRIDGE ANALYSIS
         11.19. SOLVAY
                       11.19.1. COMPANY OVERVIEW
                       11.19.2. SWOT ANALYSIS
                       11.19.3. REVENUE ANALYSIS
                       11.19.4. PRODUCT PORTFOLIO
                       11.19.5. RECENT DEVELOPEMENTS
                       11.19.6. DATA BRIDGE ANALYSIS
         11.20. 3M DRUG DELIVERY SYSTEMS
                       11.20.1. COMPANY OVERVIEW
                       11.20.2. SWOT ANALYSIS
                       11.20.3. REVENUE ANALYSIS
                       11.20.4. PRODUCT PORTFOLIO
                       11.20.5. RECENT DEVELOPEMENTS
                       11.20.6. DATA BRIDGE ANALYSIS

12. APPENDIX

13. ABOUT DATA BRIDGE MARKET RESEARCH

Did you find apk for android? You can find new Free Android Games and apps.
Want create site? Find Free WordPress Themes and plugins.

Available on Request.

Did you find apk for android? You can find new Free Android Games and apps.
Want create site? Find Free WordPress Themes and plugins.

Available on Request.

Did you find apk for android? You can find new Free Android Games and apps.
Want create site? Find Free WordPress Themes and plugins.

Please fill in the below form and our sales representatives will get back to you. Thank You

Did you find apk for android? You can find new Free Android Games and apps.
Want create site? Find Free WordPress Themes and plugins.

Did you find apk for android? You can find new Free Android Games and apps.
Did you find apk for android? You can find new Free Android Games and apps.
`